PPARA and Hepatic steatosis: Moreover, research evaluating whether the short-term administration of PPARα agonists might alleviate hepatic steatosis in steatotic livers before I/R would be of interest for clinical practice because there are obvious difficulties concerning the feasibility of long-term PPARα agonist administration in some I/R processes, in particular liver transplantation from cadaveric donors, because this is an emergency procedure in which there is very little time to pretreat the donor with PPARα agonists.